{{'Search' | translate}}
 

Fetal Bovine Serum

Company: HyClone
Catalog#: SH30070.03
Bio-protocol()
Company-protocol()
Other protocol()

Equilibrium and Kinetic Measurements of Ligand Binding to HiBiT-tagged GPCRs on the Surface of Living Cells
Author:
Date:
2020-12-20
[Abstract]  

G-protein coupled receptors (GPCRs) remain at the forefront of drug discovery efforts. Detailed assessment of features contributing to GPCR ligand engagement in a physiologically relevant environment is imperative to the development of new therapeutics with improved efficacy. Traditionally, binding properties such as affinity and kinetics were obtained using biochemical radioligand binding assays. More recently, the high specificity of resonance energy transfer has been leveraged toward the development of homogeneous cell-based proximity assays with capacity for real-time kinetic measurements. This suite of ligand binding protocols couples the specificity of bioluminescent resonance energy transfer (BRET) with the sensitivity afforded by the luminescent HiBiT peptide. The BRET format is

...
[摘要]  [摘要] G蛋白偶联受体(GPCR)仍然是药物发现工作的最前沿。对有助于GPCR配体参与生理相关环境的特征进行详细评估,对于开发具有更高功效的新疗法至关重要。传统上,使用生化放射性配体结合测定法获得结合特性,如亲和力和动力学。最近,共振能量转移的高特异性已利用向homogen发展Ë容量进行实时动态测量的OU基于细胞的邻近分析。这套配体结合方案将生物发光共振能量转移(BRET)的特异性与发光HiBiT肽提供的灵敏度相结合。BRET格式用于通过与荧光示踪剂的竞争性结合来定量配体与其同源HiBiT标签GPCR之间的动态相互作用。同时,HiBiT与细胞不可渗透的LgBiT的高亲和力互补将明亮的生物发光供体信号限制到细胞表面,并消除了细胞内区室中未被占用的受体的发光背景。


[背景] G蛋白偶联受体(GPCR)在驱动细胞信号传导途径中起关键作用,并且仍然是药物开发的重要目标类别(Santos等,2017)。因此,对于基础研究和药物发现运动而言,可以定量对于药物作用至关重要的生物物理特性的GPCR配体结合测定法是必不可少的(Fang,2012; ...

Generation of T cells from Human and Nonhuman Primate Pluripotent Stem Cells
Author:
Date:
2020-07-05
[Abstract]  Pluripotent stem cells (PSCs) have the potential to provide homogeneous cell populations of T cells that can be grown at a clinical scale and genetically engineered to meet specific clinical needs. OP9-DLL4, a stromal line ectopically expressing the Notch ligand Delta-like 4 (DLL4) is used to support differentiation of PSCs to T-lymphocytes. This article outlines several protocols related to generation of T cells from human and non-human primate (NHP) PSCs, including initial hematopoietic differentiation of PSC on OP9 feeders or defined conditions, followed by coculture of the OP9-DLL4 cells with the PSC-derived hematopoietic progenitors (HPs), leading to efficient differentiation to T lymphocytes. In addition, we describe a protocol for robust T cell generation from hPSCs conditionally ... [摘要]  [摘要] 多能干细胞(PSCs)有潜力提供同质的T细胞群体,这些细胞可以在临床规模上生长,并通过基因工程来满足特定的临床需求。OP9-DLL4是一种异位表达Notch配体Delta-like 4(DLL4)的基质细胞系,用于支持psc向T淋巴细胞的分化。本文概述了从人类和非人类灵长类(NHP)PSC中产生T细胞的几种方法,包括在OP9喂食者或特定条件下对PSC进行初始造血分化,然后将OP9-DLL4细胞与PSC衍生的造血祖细胞(HPs)共培养,从而有效地分化成T淋巴细胞。此外,我们描述了一个从有条件表达ETS1的hPSCs中产生健壮T细胞的方案。所提出的协议提供了一个平台,用于疾病建模和评估其在大型动物模型免疫治疗中的应用。

[背景] T淋巴细胞(T细胞)在细胞介导的免疫反应中起着关键作用,参与肿瘤细胞的监测和杀伤。在过去的几十年里,已经开发了几种策略来重定向、培养和/或增强抗肿瘤的T淋巴细胞(Houot等人,2015年;June等人,2018年),并将其用于基于T细胞的过继免疫治疗。最近的临床试验表明,用嵌合抗原受体(CAR)-T细胞治疗复发性和难治性淋巴瘤患者的疗效显著(Riviere和Sadelain,2017)。

人类多能干细胞(hPSCs),包括胚胎(hESCs)和诱导(hiPSCs),为生产用于过继性细胞免疫疗法的T细胞提供了一种很有前景的资源,可与基因工程技术相结合,产生现成的CAR ...

Comments